ClinicalTrials.gg
TerminatedNCT05223751PART-HFUpdated Oct 23, 2025

Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure

An interventional study of Meo Health Breathing and humming exercises in Diastolic Heart Failure, sponsored by Lancaster General Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by Lancaster General Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Enrollment goal was not reached within the allotted funding period.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Heart Failure, Diastolic with a site in United States — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure, Diastolic · United States.

Enrollment
29th of 81
65 · median 36
Started
2022
with 4 others
No phase
40 of 95
6 open now
Registered
73rd of 95
by date

Among the 95 studies in Heart Failure, Diastolic with a site in United States, this one is the 29th largest by enrollment of the 81 interventional ones that give a count, is one of 5 that started in 2022, is one of 40 with no phase, and was the 73rd registered.

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

Browse Heart Failure, Diastolic studies →

Open to participants now

18 of the 95 studies in Heart Failure, Diastolic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Heart Failure, Diastolic studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Heart Failure, Diastolic with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, randomized, controlled clinical trial in which participants with NYHA class II or III and symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) ≤ 45%) will be assigned to one of two treatment groups: standard of care or breathing therapy.

Read the detailed description

To evaluate the effect of breathing training on the 6-minute walk test in a population of heart failure patients.

Enrollment/Baseline Visit During the enrollment visit, the participant will meet with the clinical research coordinator (CRC) to review any final questions regarding the study and the informed consent form will be signed. The enrollment visit must occur within one month of screening. Once the informed consent is signed, the following procedures will occur.

  • Randomization: Participants will be randomized using REDCap in a 2:1 blocking method into the intervention group (breathing therapy) or the control (standard of care).
  • N-terminal (NT)-pro hormone BNP (NT-proBNP): If an NT-proBNP was collected as standard of care within 3 months of enrollment, this can be used for study purposes and compared to the 6 month NT-proBNP.
  • New York Heart Association Class: If the NYHA class is completed as standard of care within 3 months of enrollment, this can be used for study proposes.
  • Kansas City Cardiomyopathy Questionnaire (KCCQ)
  • Respiratory Rate
  • Peak Expiratory Flow
  • 6-minute walk test
  • Orientation to the Heart Rate Variability 4 (HRV4) Training application: This will include downloading, creating an account for, and training the participant on the application.

The Intervention Group will also receiving training on the Meo Health breathing therapy, which will include:

  • Being shown the Meo Health Breathing Therapy On-Boarding video
  • Orientation to breathing application: Participants will be assisted in downloading and custom setting the Breathe application.
  • Zoom Within one month of the baseline visit, participants in the intervention group will have a one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their breathing therapy intervention.

    3 Month Visit The 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group . The participant will only meet with the CRC at the 3 month visit and all assessments will be completed by the CRC.

  • NYHA class
  • KCCQ
  • Respiratory Rate
  • Peak Expiratory Flow
  • 6-minute walk test
  • Assess compliance from HRV4 Training application questions
  • Assess any possible adverse events

    6 Month/Final Visit The 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group. The participant will meet with the CRC at the 6 month visit, any assessments not completed as Standard of Care (SOC), will be completed by the CRC.

  • NT-proBNP: If an NT-proBNP is ordered as standard of care for the participant, this can be used for study purposes and compared to the baseline NT-proBNP.
  • NYHA class: If the NYHA class is completed as standard of care, this can be used for study purposes and compared to the baseline and 3 month values.
  • KCCQ
  • Respiratory Rate
  • Peak Expiratory Flow
  • 6-minute walk test
  • Assess any possible adverse events

    9 Month Structured Telephone Survey The 9 month structured telephone interview will take place for all participants who receive breathing training from Meo Health. Participants will be called by a study team member who will facilitate a short (3-5 minute) telephone survey about adherence and changes in health outcomes as a result of participation in the trial. (See appendix 15.4). The study team member will record all answers into REDCap. Upon completion of the survey, participants will be closed out of the study. If a study team member is unable to get in contact with a participant after two attempts, their status will be marked as "closed to follow-up" and they won't be interviewed.

03

Conditions studied

  • Diastolic Heart Failure

Keywords

  • heart failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years or older
  2. Signed
  3. class II-III heart failure
  4. EF ≤ 45% (echo within 1 year of enrollment)
  5. At least 30 days of stable medical regimen (no new neurohormonal blockade or Sodium-glucose co-transporter 2 inhibitors (SGLT2i). Dose adjustments allowed)
  6. Likely to be compliant with breath training as assessed by the provider
  7. Availability of a "smart" phone and internet access
  8. Established care at Lancaster General Health Penn Medicine

Exclusion criteria

Exclusion Criteria:

  1. Cardiac resynchronization therapy (CRT) within 6 months
  2. Severe (COPD)
  3. History of diaphragm paralysis
  4. Unable or unwilling to complete respiratory training protocol
  5. Decompensated or American College of Cardiology (ACC) Stage D Heart Failure (HF)
  6. Prior or planned chest/abdominal or nasal/facial surgery within 6 months
  7. Neuromuscular disease which impairs respiration
  8. Diagnosed cognitive impairment (unable to participate in training)
  9. Untreated obstructive severe sleep apnea (AHI > 30)
  10. Severe valvular heart disease
  11. Uncontrolled atrial fibrillation (Ave Heart Rate (HR) > 100 bpm)
  12. Orthopedic or other limitations which impair the 6-minute walk test
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    HRV4 + Breathing and Humming Training

    On a biweekly basis, and with the other members of their subgroup within the cohort, participants will meet with the Meo Health breathing coach on Zoom for approximately 30 minutes. These sessions will encourage participants to complete their daily exercises and provide additional respiratory training.

    Behavioral: Meo Health Breathing and humming exercises

  • No intervention
    HRV4 Only

    Control participants will complete the daily heart rate variability (HRV) reading using the HRV4Training application.

Interventions

  • BehavioralMeo Health Breathing and humming exercises

    The Intervention Group will receive training on the Meo Health breathing therapy, which will include: * Being shown the Meo Health Breathing Therapy On-Boarding video * Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application. * Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach. Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention. A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group. A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group.

06

What researchers measure

Primary outcomes

  1. Change from baseline to 6 months for the 6-minute walk test (6MWT)

    Distance (m) covered in six minutes from baseline to 6 months

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Kansas City Cardiomyopathy Questionnaire 12 (KCCQ12) quality of life score

    Change in Kansas City Cardiomyopathy Questionnaire 12 - Quality of Life (KCCQ12-QL) score KCCQ12-QL score corresponds to Questions 6 and 7. Responses are coded as follows: Question 6 Response It has extremely limited my enjoyment of life = 1 It has limited my enjoyment of life quite a bit = 2 It has moderately limited my enjoyment of life = 3 It has slightly limited my enjoyment of life = 4 It has not limited my enjoyment of life at all = 5 Question 7 Response Not at all satisfied = 1 Mostly dissatisfied = 2 Somewhat satisfied = 3 Mostly satisfied = 4 Completely satisfied = 5 If responses to both questions are missing, no score is computed. Otherwise, the score is calculated by taking the average of the non-missing responses and rescaling to 0-100, as follows: KCCQ12-QL = 100\*\[(average of Questions 6 and 7) - 1\]/4 Scores are scaled 0-100, where 0 denotes the lowest reportable health status and 100 the highest.

    Time frame: Baseline, 3 months, 6 months

  2. Pulmonary parameters: Peak expiratory flow

    Change in peak expiratory flow spirometry

    Time frame: Baseline, 3 months, 6 months

  3. New York Heart Association (NYHA) Class (graded I-IV) Proportion Improved 1 Class

    Proportion of subjects that decreased 1 NYHA class. NYHA Classification - The Stages of Heart Failure: Class I - Cardiac disease, but no symptoms and no limitation in ordinary physical activity. Class II - Mild symptoms and slight limitation during ordinary activity. Class III - Significant limitation in activity due to symptoms. Comfortable only at rest. Class IV - Severe limitations. Symptoms even while at rest. No NYHA class listed or unable to determine.

    Time frame: Baseline, 6 months

07

Study locations

1 site
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17604, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jun 2025, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Feb 4, 2022
StartActual
Feb 7, 2022
Primary completionActual
Jun 20, 2025
CompletionActual
Sep 12, 2025
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05223751
Lead sponsor
Lancaster General Hospital
Collaborators
Louise von Hess Medical Research Institute
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Feb 7, 2022
Primary completion
Jun 20, 2025
Completion
Sep 12, 2025
Last update
Oct 23, 2025

Study contacts

Roy Small, MD
principal investigator · Medical Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion